PF-04457845
- Generic Name
- PF-04457845
- Drug Type
- Small Molecule
- Chemical Formula
- C23H20F3N5O2
- CAS Number
- 1020315-31-4
- Unique Ingredient Identifier
- H4C81M8YYW
- Background
PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
Jazz Pharmaceuticals Reports Strong Q1 2025 Performance with $898 Million in Revenue, Advances Pipeline with Zepzelca sNDA Submission
• Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively.
• The company submitted a supplemental New Drug Application for Zepzelca in combination with atezolizumab as maintenance therapy for first-line extensive-stage small cell lung cancer, based on promising Phase 3 trial results.
• Jazz completed the acquisition of Chimerix, adding dordaviprone to its late-stage pipeline for H3 K27M-mutant diffuse glioma, with an FDA PDUFA target date of August 18, 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath